Evaluation of the uptake of tuberculosis preventative therapy for people living with HIV in Namibia: a multiple methods analysis

Clay Roscoe 1*, Chris Lockhart 1, Michael de Klerk 1, Andrew Baughman 1, Simon Agolory 1, Michael Gawanab 2, Heather Menzies 1, Anna Jonas 1, Natanael Salomo 2, Negussie Taffa 1, David Lowrance 1, Katherine Robsky 3, Deanna Tollefson 4, Eric Pevzner  5, Ndapewa Hamunime 2, Farai Mavhunga 2 and Helena Mungunda 2

Abstract

Background: In 2016, Namibia had ~ 230,000 people living with HIV (PLHIV) and 9154 new tuberculosis (TB) cases, including 3410 (38%) co-infected cases. TB preventative therapy (TPT), consisting of intensive case finding and isoniazid preventative therapy, is critical to reducing TB disease and mortality.

Methods: Between November 2014 and February 2015, data was abstracted from charts of PLHIV enrolled in HIV treatment. Fifty-five facilities were purposively selected based on patient volume, type and location. Charts were randomly sampled. The primary outcome was to estimate baseline TPT in PLHIV, using nationally weighted proportions. Qualitative surveys were conducted and summarized to evaluate TPT practices and quantify challenges encountered by healthcare workers (HCW).

Results: Among 861 PLHIV sampled, 96% were eligible for TPT services, of which 87.1% were screened for TB at least once. For PLHIV eligible for preventative therapy (646/810; 82.6%), 45.4% (294/646) initiated therapy and 45.7% (139/294) of those completed therapy. The proportion of eligible PLHIV completing TB screening, initiating preventative therapy and then completing preventative therapy was 20.7%. Qualitative surveys with 271 HCW identified barriers to TPT implementation including: lack of training (61.3% reported receiving training on TPT); misunderstandings about timing of TPT initiation (46.7% correctly reported TPT should be started with antiretroviral therapy); and variable screening practices and responsibilities (66.1% of HCWs screened for TB at every encounter). Though barriers were evident, 72.2% HCWs surveyed described their clinical performance as very good, often placing responsibility of difficulties on patients and downplaying challenges like staff shortages and medication stock outs.

Conclusions: In this study, only 1 in 5 eligible PLHIV completed the TPT cascade in Namibia. Lack of training, irregularities with TB screening and timing of TPT, unclear prescribing and recording responsibilities, and a clinical misperception may have contributed to suboptimal programmatic implementation. Addressing these challenges will be critical with continued TPT scale-up.

Keywords: Tuberculosis preventative therapy (TPT), HIV, Namibia, TPT cascade, Healthcare workers

* Correspondence: jclayroscoe@hotmail.com
1 U.S. Centers for Disease Control and Prevention, Windhoek, Namibia
Full list of author information is available at the end of the article

© The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Background

Persons living with HIV (PLHIV) have an increased risk of tuberculosis (TB) due to depletion of TB-specific T-helper cells [1, 2], increasing their risk (5–10% per year) of progressing from TB infection to TB disease [3, 4]. PLHIV are more likely to advance from TB infection to TB disease as well as have accelerated disease progression, and both factors can contribute to outbreaks of TB in PLHIV [3]. HIV also can increase the risk of recurrent TB disease in individuals with a history of prior tuberculosis [4]. Approximately one-third of all deaths among PLHIV are attributable to TB, with over 95% of TB mortality occurring in low and middle-income countries [5].

TB preventative therapy (TPT) reduces the progression from infection to TB disease in PLHIV by up to 62% and reduces mortality by up to 39%, both being independent of ART status [6–8].

Based on 2016 UNAIDS data, at the time of this study Namibia had an estimated ~230,000 PLHIV among adults ages 15+ years, with an HIV prevalence of 12.3% among adults ages 15–49 years [9]. In the same year, the WHO estimated that Namibia had 9154 cases of TB, of which 3410 (38%) were coinfected with HIV, and 870 deaths occurred among patients with TB/HIV; no data were available on isoniazid-based TPT use for PLHIV newly enrolled in HIV treatment [10]. Responding to these challenges, Namibia has been working towards implementing WHO recommendations for prevention of tuberculosis in PLHIV, including scaling up of TPT, treatment of TB disease, and early antiretroviral therapy (ART) initiation [11].

TPT was introduced in Namibia as a nation-wide program in 2006/07, with implementation outlined in The National Guidelines for Antiretroviral Therapy, Revised Second Edition. By 2009, approximately 90,000 PLHIV had been screened for TB annually (approximately 50% of PLHIV in care), and 13,989 PLHIV were prescribed TPT (~8% of total PLHIV registered in care) [12]. In 2014–15, this project was initiated to quantitatively and qualitatively evaluate TPT services in Namibia. Based on findings from this study, TPT was integrated into HIV QI projects since not all facilities evaluated had implemented this service per national guidelines. Findings from this study were also taken into consideration during the drafting of the fourth edition of the national antiretroviral guidelines in 2015.

Globally, a variety of challenges have been described with respect to the implementation of TPT in resource-limited settings [13], including: supply problems [14]; medication side effects [15]; substandard monitoring and evaluation activities [16]; inadequate health care infrastructure [17]; poor TB screening practices [18]; limited understanding of TPT by prescribers [19] and patients [20, 21]; limited access to health care [22]; HIV stigma [23]; and socio-economic issues that undermine household security [24, 25]. In Namibia, though all PLHV > 5 years old are eligible, it was not clear to what extent PLHIV were screened for TB or, when eligible, how many initiated and completed TPT. Also, challenges associated with implementation of TPT remained ill-defined, though step-wise instruction on TB symptom screening and treatment is included in the National ART and TB Treatment Guidelines (Fig. 1) [26].

We believe TPT is underreported in Namibia due to incomplete data collection for PLHIV in whom TB has been excluded or is suspected because data, from symptom screening to treatment, is captured piecemeal across two electronic and three paper data registries. These registries include: the electronic patient management system (ePMS) (captures HIV and TPT data, but not active TB data) and the electronic TB register (ETR) (captures active TB data); as well as the paper patient HIV care booklet, TB register, and TPT register (formally ITP register). Both electronic and paper databases are susceptible to incomplete data entry, and ePMS and ETR are prone to transcription errors when entering data located in paper registers. As well, data concurrence across registers can be inconsistent, and implementation of TPT in Namibia at the facility level is also thought to be highly variable.

We evaluated quantitative clinical data and qualitative programmatic practice data associated with TPT uptake in select HIV care and treatment facilities in order to establish a baseline estimate of services provided and to describe challenges faced with ongoing implementation of TPT in Namibia.

Methods

We conducted a retrospective quantitative patient chart review using facility data sources to provide a baseline assessment of TPT services in Namibia. Data sources included the two electronic databases (ePMS and ETR), as well as the three paper-based data registries (patient HIV care booklet, TB register and the TPT register). We also conducted qualitative surveys of health care workers (HCWs) to evaluate provider perspectives on TPT practices and challenges.

Sampling frame

The patient sampling frame included all PLHIV currently enrolled in HIV care during July to September 2013 as recorded in the electronic patient management system (ePMS), a national HIV database. Patients on TPT treatment during this period were expected to have treatment completion outcome data available by the time the study was implemented during November 2014 through February 2015.
The sample size for this evaluation was based on estimating the percentage of patients in HIV care receiving TPT services with sufficient precision, while accounting for between-facility variation. The true percentage of patients in HIV care (on ART and pre-ART) receiving TPT was assumed to be 50% (95% CI 45–55%). Assuming an intraclass correlation coefficient of 0.02, an average cluster size of 20, a design effect of 1.4, and taking into account the possibility of unavailable data or missing records (inflating the sample size by 5%), a sample size was estimated at 362–560 patient charts for review, corresponding to 20–50% of patients initiating TPT.

To calculate the sample size for each facility, a sampling fraction of 560 patients/163,179 total PLHIV (estimated total number of PLHIV enrolled in care in Namibia during July–September 2013) was applied to each facility included in the study. Sample size was distributed across facilities based on the proportion of PLHIV enrolled in each facility. A minimum number of 10 records were sampled per facility and, factoring in this minimum distribution, the total sample size increased to 905 patients across the 55 facilities.

**Site selection**

At the time of the study, Namibia had 13 regions containing 34 health districts with a total of 35 hospitals, 36 health centers, and 143 clinics providing HIV testing and treatment and TPT. Sites participating in this study were purposively sampled with the aim of achieving adequate representation of different facility types, sizes, and geographic regions. Site selection was based on cumulative HIV care and treatment enrollment data from July–September 2013. In total, 55 facilities were selected, representing all 13 regions and 23 of 34 health districts. One facility, Orangemund Clinic, in the Luderitz Health District, was excluded because a permit for access could not be obtained. Because this clinic was small, ultimately representing 0.08% of the overall sample, it was considered to have a minimal effect of representativeness and not replaced with an alternate.

**Data collection and analysis of the TPT cascade**

We performed a retrospective review of patient charts at each facility by evaluating the various paper and electronic data sources. We used standardized data abstraction tools to collect data on TB screening, TPT eligibility, TPT initiation and completion, as well as other clinical and demographic variables.

We summarized the demographic and clinical characteristics of people living with HIV along with select HIV-related clinical characteristics. Based on data associated with PLHIV at each facility, a TPT cascade was constructed using frequencies and percentages calculated from the number of patients reaching each of the three stages of the cascade (screened for TB, started TPT, completed TPT). The cascade was stratified by district, gender, age, training on cotrimoxazole and isoniazid (INH) prophylaxis, whether patient was on ART, and

![Algorithm for TB screening and TB-IPT among Adults and Adolescents with HIV](image-url)
type of treatment facility where HIV services were provided.

After reviewing the sample of 54 facilities selected for the study, we determined that smaller facilities were over-represented and larger facilities were under-represented in the final sample. To rectify this, a sampling weight was calculated for each PLHIV on ART in the final sample by dividing the estimated total number of PLHIV on ART seen at each patient's facility during July–September 2013, by the total number of patients sampled at that facility. Final TPT cascade percentages were then calculated using these sampling weights.

Demographic and clinical information collected from patient records included: gender, age, marital status, ART status and start date, year of entry into HIV care, HIV care entry point, and current HIV care and treatment facility.

We used the design-based Pearson's chi-square test to evaluate unadjusted bivariate associations between patient/facility factors and each stage of the TPT cascade. A p-value < 0.05 was considered statistically significant. All analyses were performed using Stata software version 15.0.

Data collection and analysis of healthcare worker surveys

Qualitative surveys were conducted with HCWs (physicians, nurses and other health care staff) potentially involved with TPT provision. Ideally, five HCWs were selected and consented for survey participation in a private location within each facility. In cases where facilities had fewer than five HCWs, all individuals were surveyed. Teams consisting of staff from Namibia Ministry of Health and Social Services (MOHSS), U.S. Centers for Disease Control and Prevention (CDC) Namibia, and CDC Atlanta conducted surveys using a semi-structured questionnaire designed to assess knowledge and identify barriers and challenges associated with implementation of the TPT cascade in PLHIV. The survey was divided into three broad areas: practices and procedures used by HIV care and treatment facilities for implementing TPT programs; TB evaluation and diagnosis; and final comments. Surveys were recorded and then transcribed for analysis. The majority of questions were semi-structured, close-ended (multiple choice), as well as some open-ended questions defined to elicit short responses. A traditional qualitative analysis was not performed as all responses tended to be one word or a short phrase, based on the nature of the questions (designed to be short answer) and how data were collected (interviewer summarized the response). As a result, open-ended data lent itself to being quantified precisely.

We analyzed survey data using Nvivo 11.0 qualitative analysis software. Basic attributional data on HCWs (e.g., socio-demographic and occupational characteristics) were summarized, and an analytical framework was developed to facilitate coding of individual responses according to specific themes and sub-themes. Themes were reviewed and refined on a weekly basis via inter-group discussions that included representatives of the CDC, MOHSS, and public health experts from the University of Washington and Johns Hopkins University. Individuals from MOHSS were particularly important to this process, representing multiple years of frontline experience working with PLHIV and TB in health facilities across Namibia. This approach was meant to reduce investigator bias during the data analysis phase, particularly with respect to qualitative data and the various themes discussed. Relationships between attributional and thematic data were analyzed and summarized using basic descriptive statistics.

Results

Study population

The final sample consisted of 861 PLHIV. Median age was 33 years, 59.5% were female, and most were on ART (82%), with more than half (53.7%) entering care in 2010 and 2011 (3 or 4 years prior to the study). Over half of the PLHIV in the study (54%) reported self-referring to HIV care, and a clear majority stated they received current HIV care and treatment in a hospital setting (81.9%) (Table 1).

Quantitative findings on the TPT Cascade

Of 861 PLHIV in the sample population, 36 (4.2%) were excluded per National Guidelines (i.e. already on TB treatment prior to enrollment, had started TB treatment the same day as HIV enrollment, or because TB treatment had been started but the timing of treatment with respect to enrollment in HIV care was unknown) [27]. Of those sampled, 825 (95.8%) were eligible for TPT, though 15 were missing information on TB screening. Accounting for sampling weights, 87.1% (679/810) of PLHIV eligible for TB screening were actually screened, of which 16.8% (102/679) screened positive and were referred for diagnostic evaluation for TB disease (see Fig. 2). Of those referred, 25.8% (29/102) were started on TB treatment; the remaining individuals referred for evaluation did not start TB treatment (69.4%; 69/102) or treatment status was unknown (4.8%; 4/102). The total proportion of individuals eligible for preventative therapy (82.6%, 646/810) included individuals who screened negative and were not referred for TB testing, and individuals referred for TB testing but who did not start TB treatment. Of the total patients eligible for preventative therapy, 45.4% (294/646) started and 45.7% (139/294) of those who started completed a course of therapy. Overall, the weighted proportion of patients eligible for TPT who initiated and also completed therapy was 20.7% (139/646) (Figure 2). When the three steps of
| Characteristic | Number of Patients | Sample % | Weighted % |
|---------------|--------------------|----------|------------|
| **Sex**       |                    |          |            |
| Female        | 485                | 60.7     | 59.5       |
| Male          | 314                | 39.3     | 40.5       |
| Unknown       | 62                 | 7.2      | 7.8        |
| **Age (years), median (IQR)** | 746 | 33 (27–40) | 33 (27–40) |
| **Age Group (years)** | | | |
| 0–14          | 2                  | 3.9      | 4.2        |
| 15–24         | 105                | 14.1     | 13.1       |
| 25–34         | 292                | 39.1     | 39.9       |
| 35–44         | 201                | 26.9     | 28.3       |
| 45–54         | 83                 | 11.1     | 10.5       |
| 55+           | 36                 | 4.8      | 4.1        |
| Unknown       | 115                | 13.4     | 12.9       |
| **Marital Status** |                |          |            |
| Single        | 570                | 71.7     | 72.5       |
| Married       | 172                | 21.6     | 20.3       |
| Other         | 53                 | 6.7      | 7.2        |
| Unknown       | 66                 | 7.7      | 6.6        |
| **ART Status** |                    |          |            |
| On ART        | 640                | 79.9     | 82.0       |
| Not on ART    | 161                | 20.1     | 18.0       |
| Unknown       | 60                 | 7.0      | 7.7        |
| **Year of HIV Care Entry** | | | |
| < 2009        | 61                 | 7.3      | 7.5        |
| 2009          | 46                 | 5.5      | 5.2        |
| 2010          | 225                | 26.8     | 29.8       |
| 2011          | 208                | 24.8     | 23.9       |
| 2012          | 192                | 22.9     | 22.2       |
| 2013          | 104                | 12.4     | 10.8       |
| 2014          | 3                  | 0.4      | 0.5        |
| Unknown       | 22                 | 2.6      | 2.8        |
| **HIV Care Entry Point** | | | |
| Medical/Inpatient | 167          | 24.0     | 25.8       |
| PMTCT         | 105                | 15.1     | 14.1       |
| Self-referral | 381                | 54.7     | 54         |
| TB Clinic     | 17                 | 2.4      | 1.8        |
| Private       | 10                 | 1.4      | 2.0        |
| All Others    | 16                 | 2.3      | 2.2        |
| Unknown       | 165                | 19.2     | 17.3       |
| **Current HIV Care and Treatment Facility** | | | |
| Clinic        | 239                | 27.8     | 5.8        |
| Health Center | 176                | 20.4     | 12.3       |
| Hospital      | 466                | 51.8     | 81.9       |

*Unknown values are not included in the percent distribution of the characteristic*
the TPT cascade were evaluated by district and key patient
variables, TPT initiation and completion rates did not vary
in terms of any patient variables, with the exception that
patients on ART were more often screened for TB, com-
pared to those not on ART (94.6% vs. 66.1%, \( p < 0.01 \)),
and that they were more often eligible for IPT (89.2% vs.
63.8%, \( p < 0.01 \)). (Table 2).

Qualitative healthcare worker surveys

Overall, 271 HCWs were surveyed, with 16.9% working
at hospitals, 33.2% at health centers and 49.9% at clinics.
The largest occupational group was nurses (61.3%, 166/
271), while physicians/doctors made up the fewest
number of individuals surveyed (1.8%, 5/271). Not all
participants answered all questions (answered ‘Don’t
Know’ or answer was missing). Based on participant re-
ponses, several potential barriers to effective implemen-
tation of the TPT cascade were identified and are
summarized into five broad categories below, with fre-
quencies based on the number of respondents (n) for
each question. Key findings are summarized below and in
Table 3).

Lack of training

Overall, 61.3% of HCWs (106/173) reported receiving
training on TB screening, while 38.7% (67/173) reported
they had not received training on providing preventative
therapy. Also, 28.5% of HCWs (75/263) highlighted the
need for staff training when asked to provide suggestions
regarding the management of TB and HIV at their re-
spective facilities.

Timing of preventative therapy initiation

Responses regarding the timing of preventative therapy ini-
iation relative to ART initiation varied considerably
among HCWs. Overall, 46.7% of HCWs (70/150) reported
starting therapy at the same time as ART, while 53.3% (80/
150) reported that it was given after initiating ART or did
not know when to initiate treatment. HCWs based at
health centers and clinics were more likely to report start-
ing TPT and ART around the same time (49.2 and 52.1%,
respectively), compared to those who worked at hospitals
(35.9%). Several reasons were provided for not initiating
TPT and ART at the same time, including: the need to
monitor and minimize side effects, a belief that overlapping
treatment was not allowed, uncertainty as to whether the
patient had latent TB, and because they wanted to have
time to assess the impact of ART before initiating TPT.

TB screening practices

Overall, 66.1% of HCWs (111/168) reported that PLHIV
were screened for TB during every clinic visit, while
33.9% (57/168) reported PLHIV were not screened at
every visit. Screening practices varied considerably, espe-
cially in terms of following WHO guidelines for screen-
ing for TB disease (presence of any of the following:
current cough, weight loss, night sweats, and/or fever)
[12]. At the time of this survey, National ART Guide-
lines for Namibia recommended screening for these four
symptoms, as well as fatigue, blood in sputum, chest
pain, diarrhea, shortness of breath, and loss of appetite.
While most HCWs reported asking about the four
symptoms recommended by WHO, many listed other
symptoms and combinations of symptoms that did not
always include the four [28].
There was considerable variation across both occupations and facility types with respect to who was responsible for implementing different aspects of the TPT cascade. When asked who was responsible for screening for TB disease at their respective facilities, 84.6% (148/175) replied that it was at least partly the responsibility of nurses. However, 61.1% (107/175) identified a variety of other individuals who were responsible for TB screening, including: physicians, community health workers (provide services and health promotion, including TPT, in their own village or community), TB field promoters (part of the national TB program: visiting households, performing symptom screening, and facilitating treatment), health assistants (local clinic or health center staff member), and others.

When HCWs were asked who was responsible for prescribing TPT medication, 76.9% (130/169) identified nurses, and 43.8% (74/169) indicated physicians (in some cases, individuals indicated both nurses and physicians). Respondents who worked at hospitals were more likely to identify physicians as providers of TPT (55.0%, 33/60), while those who worked at health centers and clinics were more likely to identify nurses (61.9% (39/63) and 74.7% (65/87), respectively).

### Responsibilities and recording

**Table 2: TPT Cascade for PLHIV by Key Patient and Facility Variables, Namibia, 2014–2015**

| Patient/Facility Characteristic | Among patients eligible for TB screening, unweighted proportion screened for TB, weighted % (95% CI) | Among patients eligible for TPT, unweighted proportion initiated TPT, weighted % (95% CI) | Among patients initiated TPT, unweighted proportion completed treatment, weighted % (95% CI) |
|--------------------------------|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|
| Total                          | 679/810, 87.1 (82.2–90.9)                      | 646/810, 78.7 (76.8–87.2)                      | 294/646, 45.4 (36.7–54.4)                      |
|                                |                                                 | 139/294, 45.7 (32.0–60.0)                      | 139/646, 20.7 (13.6–30.4)                      |
| Sex                            |                                                 |                                                 |                                                 |
| Female                         | 390/466, 86.6 (81.2–90.6)                      | 375/465, 83.3 (77.0–87.9)                      | 180/375, 48.2 (37.6–59.0)                      |
|                                |                                                 | 89/180, 48.4 (34.2–62.8)                       | 89/375, 23.3 (15.3–33.8)                       |
| Male                           | 237/287, 84.6 (78.8–91.5)                      | 220/287, 79.8 (70.2–86.9)                      | 92/220, 43.4 (33.3–54.0)                       |
|                                |                                                 | 46/92, 47.2 (30.5–64.5)                        | 46/220, 20.4 (12.2–32.1)                       |
| Age group (years)              |                                                 |                                                 |                                                 |
| 0–14                           | 21/28, 83.0 (60.2–94.1)                        | 21/28, 83.0 (60.2–94.1)                        | 4/21, 19.1 (11.6–29.8)                         |
|                                |                                                 |                                                 | 2/4, 5.1–85.4 (1.2–31.4)                       |
| 15–24                          | 82/99, 91.4 (78.7–96.8)                        | 79/99, 89.4 (76.9–95.6)                        | 40/79, 48.4 (26.5–70.9)                        |
|                                |                                                 |                                                 | 41.0 (23.8–60.6)                               |
| 25+                            | 491/577, 87.3 (82.3–91.1)                      | 466/577, 82.4 (76.4–87.0)                      | 225/466, 48.3 (40.4–56.4)                      |
|                                |                                                 |                                                 | 108/215, 47.2 (32.0–62.9)                      |
|                                |                                                 |                                                 | 22.8 (15.1–32.9)                               |
| Received Education on CTX/INH Prophylaxis |                                                 |                                                 |                                                 |
| Yes                            | 205/237, 86.6 (79.4–91.6)                      | 196/237, 83.0 (73.3–89.7)                      | 95/196, 48.4 (36.1–60.9)                       |
|                                |                                                 |                                                 | 44.2 (29.3–60.3)                               |
| No                             | 192/213, 89.4 (81.4–94.2)                      | 181/213, 84.0 (78.3–88.4)                      | 91/181, 49.7 (40.3–59.1)                       |
|                                |                                                 |                                                 | 50.1 (28.7–71.5)                               |
| ART status                     |                                                 |                                                 |                                                 |
| On ART                         | 524/597, 94.6 (90.9–96.9)                       | 524/597, 94.6 (89.0–92.8)                      | 245/524, 47.1 (38.2–56.2)                      |
|                                |                                                 |                                                 | 47.7 (32.9–62.9)                               |
| Not on ART                     | 91/155, 63.8 (45.4–78.9)                       | 38/91, 40.3 (27.6–51.6)                        | 31.8 (16.8–51.9)                               |
| Current HIV Care and Treatment Facility |                                                 |                                                 |                                                 |
| Clinic                         | 174/227, 78.7 (59.9–90.2)                      | 171/227, 78.4 (59.3–90.0)                      | 73/171, 40.2 (27.6–52.8)                       |
|                                |                                                 |                                                 | 34/73, 25.8 (11.3–48.6)                        |
|                                |                                                 |                                                 | 12.9 (5.9–26.0)                               |
| Health                         | 121/162, 85.9 (78.3–91.1)                      | 121/162, 75.7 (67.1–82.6)                      | 60/121, 42.7 (28.9–57.7)                       |
|                                |                                                 |                                                 | 37.5 (26.2–50.3)                               |
| Center                         | 354/421, 87.9 (82.0–92.1)                      | 354/421, 84.0 (77.4–88.9)                      | 161/354, 45.4 (35.3–56.0)                      |
|                                |                                                 |                                                 | 78/161, 48.2 (32.0–64.8)                       |
|                                |                                                 |                                                 | 21.9 (13.5–33.5)                               |

**NOTE:** all other bivariate associations were not statistically significant (p < 0.05)

*a* (94.6% vs. 66.1%, *p* < 0.01)

*b* (89.2% vs. 63.8%, *p* < 0.01)
Though only a small number of HCWs \((n = 14)\) responded to the question asking who was responsible for the TPT data checking process, respondents identified a wide variety of positions, including: data clerks, nurses, pharmacists, pharmacy assistants, community counselors, community health workers, physicians, and TB field promoters. Variability in TPT data checking practices was also observed. Specifically, HCWs reported checking many record types, including the preventative therapy register, patient care booklet, health passport, ePMS, and the ART booklet. When asked if they cross-checked data from the TPT register with information from patient care booklets, only 39.9% \((59/148)\) reported doing so.

### Clinician perceptions

A consistent response pattern among HCWs was noted when asked to assess the performance of their respective facilities. In almost every instance, HCWs described clinical performance as very good, while downplaying any problems and/or ascribing problems related to TPT uptake to patient behaviors. For example, when asked what concerns they had regarding TPT, the most common response among HCWs’ was “none” \((34.8\%, 47/135)\), followed by concerns regarding patient behavior that was notably negative or problematic, individual responses included general resistance, missed appointments, lack of education, forgetfulness, and movement or migration. Similarly, when asked what concerns their patients might have regarding TPT, 53.3% \((73/137)\) of

| Table 3 Indicators of implementation of the TPT cascade based on surveys of 271 health care workers in Namibia, 2014–2015 |
|----------------------------------------------------------|-------------------------------------------------|-----------------|
| **Indicator of ICF/TPT cascade implementation (n)** | **Number of HCWs** | **%** |
| **IMPLEMENTATION** | Yes | 106 | 61.3 |
| | Yes | 67 | 38.7 |
| | Reported starting TPT at the same time as ART \((n = 150)\) | Yes | 70 | 46.7 |
| | No | 80 | 53.3 |
| | Reported that PLHIV were screened for TB during every clinic visit \((n = 168)\) | Yes | 111 | 66.1 |
| | No | 57 | 33.9 |
| **RESPONSIBILITY** | Nurse +/- Other | 148 | 84.6 |
| | Other Only | 107 | 61.1 |
| | Who is responsible for conducting TB screening at your health facility? \((n = 175)\) | Nurse (or nurse + physician) | 130 | 76.9 |
| | Physician Only | 74 | 43.8 |
| | Who is responsible for prescribing TPT at your health facility? \((n = 169)\) | Nurse | 73 | 53.3 |
| | Physician Only | 64 | 46.7 |
| **CLINICIAN PERCEPTION** | None | 47 | 34.8 |
| | Some | 88 | 65.2 |
| | What concerns do you have concerning TPT? \((n = 135)\) | None | 73 | 53.3 |
| | Some | 64 | 46.7 |
| | What concerns do your patients have regarding TPT? \((n = 137)\) | None | 78 | 72.2 |
| | Some | 30 | 27.8 |

\*Denominators vary by indicator because not all health care workers answered all interview questions, and some questions allowed for multiple responses that could be mutually inclusive.
HCW’s responded that patients had no problems. Also, 72.2% of individuals surveyed (78/108) responded that their facility was doing a good job of getting PLHIV on TPT, and 80.2% (81/101) believed they were doing a good job of diagnosing and reporting on latent TB. Finally, when HCWs were asked why a patient with TB might not get diagnosed at their facility, the most common response was that such occurrences never happened (25.9%, 30/116), followed by responses that it depended entirely on patient disclosure (20.7%, 24/116).

Discussion
This study represents the first comprehensive assessment of the TPT cascade for PLHIV in Namibia, as well as the first evaluation of facility-based experiences with TPT implementation and its associated challenges. Based on our retrospective data review of TPT uptake in PLHIV, we noted major missed opportunities and practices inconsistent with WHO recommendations at each step of the cascade. Not all PLHIV were screened for TB, preventative therapy initiation was observed for less than half of eligible patients, and overall only 20.7% of PLHIV who were eligible for therapy actually started and completed a course of preventive therapy. Losses at each step of the TPT cascade represent opportunities to improve the diagnosis, treatment, and prevention of the leading cause of death, TB, among PLHIV.

When comparing these quantitative findings to survey responses from the HCW questionnaire, specific challenges and perceptions were identified that could contribute to low uptake of the TPT cascade in Namibia. Most notable was a lack of training among HCWs on TB screening and initiation of preventative therapy, which may contribute to poor uptake of TPT services for PLHIV.

HCWs also reported several practices that may contribute to poor implementation of the TPT cascade. There was considerable variation in the timing of preventative therapy initiation relative to ART initiation, which contradicts current recommendations that TPT and ART should be given concomitantly or near-concomitantly [29]. Variable understanding and clinical opinions about when to initiate TPT and ART could result in providers delaying treatment, leading to decreased uptake. HCWs also identified a wide variety of individuals responsible for implementing TPT, and who was responsible for data recording. Relatedly, several different recording procedures were identified, as well as lack of clear job duties and variability in data recording of TPT services, all which may be contributing to low TPT uptake. Finally, HCWs reported low rates of routine screening for TB in HIV-positive patients, which is in direct contrast to WHO and National Guidelines that recommend all PLHIV should be screened at every health care visit [10].

Another issue observed was the wide use of a variable and sometimes-expanded list of symptoms for screening for TB. Given that the sensitivity of screening practices based solely on the four symptoms classically associated with TB disease has been estimated at 90%, the benefit associated with use of an expanded list of symptoms is questionable. A simplified screening rule based on any one of the four classic symptoms may be more effective in resource-constrained settings when identifying PLHIV in need of further diagnostic assessment for active TB disease. Using a simplified, evidence-based symptom screening approach could result in more efficient TB screening, diagnosis and treatment, as well as efficient scale-up of TPT [30, 31].

Finally, the presence of a “clinical bias” among some respondents was evident. The concept has been of interest to researchers for some time [32–34], though few if any references have been made to it in the context of TPT. We believe clinical bias should be given serious consideration, particularly in light of the notable disconnect demonstrated in this study between the low completion rates of the TPT cascade and the high marks demonstrated in this study between the low completion rates of the TPT cascade and the high marks that the majority of HCWs gave themselves. In fact, few if any HCWs indicated having any problems when it came to providing TPT services. Many HCWs even projected this outlook onto their patients, whom they believed would have few if any problems if asked about therapy initiation and adherence. HCWs also demonstrated a tendency to link any problems that did arise to patients, citing “negative” or “problematic” patient behavior to explain potential challenges leading to poor implementation of TPT.

While patient-centered challenges do exist, the tendency for HCWs to blame patients while overestimating provider and health facility performance suggests an entrenched culture where HCWs minimize or overlook the true extent and nature of challenges faced by their patients with respect to preventative therapy initiation and adherence. Such a clinical bias can reinforce negative practices associated with poor implementation of TPT; the consequences of which may not always be easily recognized by HCWs themselves. Effective scale-up of TPT has been shown to be successful when HCWs receive more comprehensive training that fosters an enabling environment, promotes a patient-centered model of care, and sensitizes them to the wider community context [35].

The findings from this evaluation continue to inform how to optimize the TPT cascade in Namibia, including by developing a comprehensive training for all HCWs that includes standardized TPT algorithms, standard operating procedures and administrative tools that can
identify and address practices that may interfere with effective intensive case finding and preventative therapy. Similar barriers identified in this study have been identified in TPT evaluations completed in other countries in Africa, including the lack of services and medication availability, provider concern about promoting drug resistance, lack of clarity about appropriate candidates, and viewing TPT as a low priority among competing healthcare needs. Additionally, recent analyses in South Africa/Uganda, Zimbabwe and Tanzania described TPT cascade completion rates between 15 and 49%, similar to what was observed in Namibia [36–38].

Finally, between 2017 and 2019, a CDC follow-up evaluation of TPT in 16 countries (including Namibia) estimated the proportion of ART patients who underwent TB symptom screening increased from 54 to 84%. This study also reported that TB symptom screening among ART patients, by country, ranged from 35 to 108%. Improvements may have been higher than reported as TB symptom screening results were missing for >10% of ART patients screened in several countries, including in Namibia [39].

The variability in TPT provision observed in this study and others highlights the continued need to reinforce clear, consistent policies to ensure TB symptoms are investigated and appropriate TB preventative therapy is started and completed. Findings from this study also point out the need for comprehensive, standardized TPT training that addresses the concept of clinical bias and how to recognize and overcome it, especially through the use of objective, evidence-based job performance tools and programs that facilitate communication between health care providers and the general public.

Limitations
Because sites were purposively sampled, the findings may not comprise a completely representative sample generalizable to all HIV care and treatment services in Namibia. Data abstractors working on the quantitative data may not have been completely blinded to the hypothesis, which may have introduced reviewer bias. Also, as mentioned in Methods, smaller facilities were over-represented and larger facilities were under-represented in the final sample, and a sampling weight was calculated for each PLHIV on ART in the final sample to better reflect the true TPT cascade percentages. Our weighted analysis assumed that larger facilities were homogenous with respect to TPT practices and also may have resulted in increased sampling variance. Qualitative data was obtained using availability sampling, which could have made the findings vulnerable to selection bias and sampling error.

Conclusions
In Namibia, during 2014–15, the number of eligible PLHIV observed completing the TPT cascade (screening, initiating therapy, completing therapy) was relatively low (20.7%). Surveyed HCWs identified several challenges, including lack of training, irregularities with respect to TB screening practices and timing of TPT initiation, and poorly defined responsibilities and recording procedures. A possible clinical bias was observed in some HCW responses, potentially contributing to misperceptions about TPT practices and patient behaviors, both which could hinder effective implementation. Recognizing these challenges have led to continued development of new strategies to optimize TPT service provision, including increasing trainings on TPT for healthcare workers, ensuring that MOHSS Clinical Mentors closely support TPT implementation, and applying patient-centered service delivery models and education. The strategies described here are expected to continue to enhance successful implementation of TPT and resultant decreases in TB incidence and associated mortality in Namibia.

Abbreviations
AR: Presidents Emergency Plan for AIDS Relief; PLHIV: Persons living with HIV; TB: Tuberculosis; TPT: Tuberculosis preventative therapy

Acknowledgements
The authors would like to acknowledge Leigh Ann Miller, Anita Beukes, Michael Melgar, Namibia’s Ministry of Health and Social Services and the United States Centers for Disease Control and Prevention for their support.

Disclosure statement
The findings and conclusions in this manuscript are those of the authors and do not necessarily represent the official position of the funding agencies.

Authors’ contributions
CR contributed to data analysis and interpretation, led drafting of the article, performed critical revisions of the article, and facilitated final approval of the version to be published; CL contributed to data analysis and interpretation, led drafting of the article, performed critical revisions of the article, and facilitated final approval of the version to be published; MDK contributed to data collection and data analysis and interpretation; AB contributed to data collection, analysis and interpretation, performed critical revisions of the article, and facilitated final approval of the version to be published; SA contributed to research conception and design and performed critical revisions of the article; MG contributed to research conception and design, contributed to data collection and performed critical revisions of the article; NT contributed to research conception and design, contributed to data collection and data analysis and interpretation; [HM]1 contributed to research conception and design, contributed to data collection and data analysis and interpretation, and performed critical revisions of the article; AJ contributed to research conception and design, contributed to data collection, and performed critical revisions of the article; NS contributed to research conception and design, contributed to data collection and interpretation, and performed critical revisions of the article; AT contributed to research conception and design, contributed to data collection and data analysis and interpretation, performed critical revisions of the article; DL contributed to research conception and design, contributed to data collection and analysis and interpretation, and performed critical revisions of the article; CR contributed to research conception and design, contributed to data collection and analysis and interpretation, and performed critical revisions of the article; DT contributed
to research conception and design, contributed to data collection and analysis and interpretation, and performed critical revisions of the article; EP contributed to research conception and design, contributed to data analysis and interpretation, and performed critical revisions of the article; NH contributed to research conception and design, contributed to data collection and analysis and interpretation, and performed critical revisions of the article. All authors have read and approved the manuscript.

Funding
This manuscript was supported by PEPFAR through the CDC under the terms of a cooperative agreement (CGH 001181). This single cooperative agreement supported all efforts by all authors to complete the study design, data collection, data analysis and interpretation, and the final writing of this manuscript. PEPFAR had no direct role in the design of the study, nor in the collection, analysis, and interpretation of data or in writing the manuscript. The findings and conclusions in this manuscript are those of the authors and do not necessarily represent the official position of the funding agencies.

Availability of data and materials
The datasets used and/or analyzed during the current study are available from CDC Namibia on reasonable request.

Ethics approval and consent to participate
The protocol was approved by the Permanent Secretary of Health, through the Biomedical Research Ethics Committee of the Research Management Unit of the Namibian Ministry of Health and Social Services, as well as the Biomedical Research Ethics Committee of the Research Management Unit of the Namibian Ministry of Health and Social Services, as well as reviewed in accordance with the CDC, Atlanta, GA, human research protection procedures and was determined to be routine program evaluation. Consent to participate and consent for publication were not applicable. No administrative permissions were required to access the raw data for this study.

Consent for publication
Not applicable.

Competing interests
All authors declare no competing interests.

Author details
1U.S. Centers for Disease Control and Prevention, Windhoek, Namibia.
2Ministry of Health and Social Services of Namibia, Directorate of Special Programs, Oshakati, Namibia. 3Johns Hopkins University, Baltimore, USA. 4University of Washington, Seattle, USA. 5U.S. Centers for Disease Control and Prevention, Atlanta, Georgia.

Received: 25 April 2020 Accepted: 17 November 2020
Published online: 01 December 2020

References
1. Geldmacher C, Schuetz A, Ngwenyama N, et al. Early depletion of Mycobacterium tuberculosis-specific T helper 1 cell responses after HIV-1 infection. J Infect Dis. 2000;181(1):190.
2. Holmes CB, Wood R, Badri M, et al. CD4 decline and incidence of opportunistic infections in Cape Town, South Africa: implications for prophylaxis and treatment. J Acquir Immune Defic Syndr. 2000;23(1):75.
3. D'Alley CL, Small PM, Schecter GF, et al. An outbreak of tuberculosis with accelerated progression among persons infected with the human immunodeficiency virus. An analysis using restriction-fragment-length polymorphisms. N Engl J Med. 1992;326:231.
4. Lahey T, Mackenzie T, Arbelt RD, et al. Recurrent tuberculosis risk among HIV-infected adults in Tanzania with prior active tuberculosis. Clin Infect Dis. 2013;56:151.
5. World Health Organization. Tuberculosis Fact Sheet. 2017. Accessed at: http://www.who.int/mediacentre/factsheets/fs104/en.
6. Whalen CC, Johnson JL, Okwera A, et al. A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. Uganda-Case Western Reserve University Research Collaboration. N Engl J Med. 1997;337:801.
7. Abossie A, Yohannes T. Assessment of isoniazid preventive therapy in the reduction of tuberculosis among ART patients in Arba Minch hospital, Ethiopia. Ther Clin Risk Manag. 2017;13:361–6.
8. Badje A, Moh R, Gabillard D, et al. Effect of isoniazid preventive therapy on risk of death in west African, HIV infected adults with high CD4 cell counts: long-term follow-up of the Temprano ANRS 12131 trial. Lancet Glob Health. 2017;5:e1080–9.
9. (http://www.unaids.org/en/regionscountries/countries/namibia).
10. WHO 2016 Country Profile, TB. Accessed at: https://extranet.who.int/stee/Reports/bcp?RepLetter=name=AWHO_HQ_Reports/G2/PROD/EXT/ TBCountryProfile&ISO2=NA&output=type=html).
11. WHO, 2011. Guidelines for intensified case-finding and isoniazid preventative therapy for PLHIV in resource-constrained settings. Accessed at: (http://apps.who.int/iris/bitstream/10665/44472/1/9789241550708_eng.pdf).
12. van Gorkom J, Mavhunga F, Omer AO, et al. TB Control in Namibia 2002–2011: Progress and Technical Assistance. Open Infect Dis J. 2013;7(Suppl 1):M23–9.
13. Surte D, Interveran JD, Pathmanathan I, et al. Policies, practices and barriers to implementing tuberculosis preventive treatment-35 countries, 2017. Int J Tuberc Lung Dis. 2019;23(12):1308–13.
14. Teklay G, Teklu T, Legesse B, et al. Barriers in the implementation of isoniazid preventive therapy for people living with HIV in northern Ethiopia: a mixed quantitative and qualitative study. BMC Public Health. 2016;16:840. https://doi.org/10.1186/s12889-016-3525-8.
15. Maharaj B, Gengiah TN, Yende-Zuma N, et al. Implementing isoniazid preventive therapy in a tuberculosis treatment-experienced cohort on ART. Int J Tuberc Lung Dis. 2017;21(S):S37–43.
16. Getahun H, Granich R, Sculier D, et al. Implementation of isoniazid preventative therapy for PLHIV worldwide: barriers and solutions. AIDS. 2010;24(suppl 5):S57–65.
17. Cowan J, Cowan JG, Bamhart S, et al. A qualitative assessment of challenges to tuberculosis prevention and management in northern Ethiopia. Int J Tubercul Lung Dis. 2013;17(8):1071–5. https://doi.org/10.5588/ijtld.12.0240.
18. Charles M, Lindegren M, Weter C, et al. Implementation of tuberculosis intensive case finding, isoniazid preventive therapy, and infection control (“three fs”) and HIV-tuberculosis service integration in lower income countries. PLoS One. 2016;11(4):e0153243. https://doi.org/10.1371/journal.pone.0153243.
19. Lester R, Hamilton R, Charalambous S, et al. Barriers to implementation of isoniazid preventative therapy in HIV clinics: a qualitative review. AIDS. 2010; 24(suppl 5):S54–8.
20. Gust DA, Mosimaneotsile B, Mathubela U, et al. Risk factors for non-adherence and loss to follow-up in a three-year clinical trial in Botswana. PLoS One. 2016;11(4):e018435. https://doi.org/10.1371/journal.pone.018435.
21. Mindachew M, Denbev A, Memiah F, et al. Perceived barriers to the implementation of isoniazid preventive therapy for people living with HIV in resource constrained settings: a qualitative study. Pan Afr Med J. 2016;17:26. https://doi.org/10.11604/pamj.2014.17.26.2641.
22. Jacobson KB, Nicolai L, Mtwungwa N, et al. It’s about my life: facilitators and barriers to isoniazid preventive therapy completion among people living with HIV in rural South Africa. AIDS Care. 2016;28(9):936–42. https://doi.org/10.1080/09540121.2017.1283390.
23. Ayelle HT, van Mourik MS, Bonten MJ. Predictors of adherence to isoniazid preventive therapy in people living with HIV in Ethiopia. Int J Tuberc Lung Dis. 2016;20(10):1342–7. https://doi.org/10.5588/ijtld.15.0805.
24. Codecasa LR, Murgia N, Ferrarese M, et al. Isoniazid preventive treatment: predictors of adverse events and treatment completion. Int J Tuberc Lung Dis. 2013;17(1):903–8. https://doi.org/10.5588/ijtld.12.0677.
25. Nakansuka T, Taddesse HB, Booth A. Factors associated with adherence to treatment with isoniazid for the prevention of tuberculosis among people living with HIV/AIDS: a systematic review of qualitative data. PLoS One. 2014;9(2):e87166. https://doi.org/10.1371/journal.pone.0087166.
26. Republic of Namibia, Ministry of Health and Social Services. National Guidelines for Antiretroviral Therapy, Revised Fourth Edition. 4th ed. Windhoek, Namibia: MoHSS, DSP, NTLP, private bag 13198, 2014.
27. Republic of Namibia, Ministry of Health and Social Services. National Guidelines for the Management of Tuberculosis. 5th ed. Windhoek, Namibia: MoHSS, DSP, NTLP, private bag 13198, 2015.
28. Republic of Namibia, Ministry of Health and Social Services. National Guidelines for the Management of Tuberculosis. 3rd ed. Windhoek, Namibia: N, DSP, NTLP, private bag 13198, 2010.
29. Yirdaw KB, Jerene D, Gashu Z, et al. Beneficial effect of isoniazid preventive therapy and antiretroviral therapy on the incidence of tuberculosis in people living with HIV in Ethiopia. PLoS One. 2014;9(8):e104557. https://doi.org/10.1371/journal.pone.0104557.

30. Getahun H, Kittikraisak W, Heilig CM, et al. Development of a standardized screening rule for tuberculosis in people living with HIV in resource-constrained settings: individual participant data meta-analysis of observational studies. PLoS Med. 2011;8(1):e1000391. https://doi.org/10.1371/journal.pmed.1000391.

31. Cain KP, McCarthy KD, Heilig CM, et al. An algorithm for tuberculosis screening and diagnosis in people with HIV. N Engl J Med. 2010;362:707–16.

32. Foucault M. The birth of the clinic. New York: Pantheon Books; 1973.

33. Kleinman A. Patients and healers in the context of culture. Berkeley: University of California Press; 1980.

34. Lock M, Gordon D, editors. Biomedicine examined. Boston: Kluwer; 1988.

35. Pathmanathan I, Ahmedov S, Pevzner E, et al. TB preventive therapy for people living with HIV — key considerations for scale-up in resource-limited settings. Int J Tuberc Lung Dis. 2019;23(6):596–605.

36. Shapiro AE, van Heerden A, Schaafsma TT, et al. Completion of the tuberculosis care cascade in a community based HIV linkage-to-care study in South Africa and Uganda. J Int AIDS Soc. 2018;21:e25065.

37. Robert M, Todd J, Ngowi BJ, et al. Determinants of isoniazid preventive therapy completion among people living with HIV attending care and treatment clinics from 2013 to 2017 in Dar Es Salaam region, Tanzania A cross-sectional analytical study. BMC Infect Dis. 2020;20:276.

38. Nyathi S, Dlodlo RA, Satyanarayana S, et al. Isoniazid preventive therapy: uptake, incidence of tuberculosis and survival among people living with HIV in Bulawayo, Zimbabwe. PLoS One. 2019;14(10):e023076. https://doi.org/10.1371/journal.pone.023076.

39. Melgar M, Nichols C, Cavanaugh S, et al. Tuberculosis preventive treatment scale-up among antiretroviral therapy patients — 16 countries supported by the U.S. President’s Emergency Plan for AIDS Relief, 2017–2019. MMWR. 2020;69(12):329–34.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.